1 in 40 couples is at risk of having a child affected by a recessive genetic disease, often without knowing it. These conditions account for 20% of infant mortality and 18% of pediatric hospitalizations.
HERES Carrier Screening is an advanced genetic screening solution that analyzes whether you and your partner are carriers of recessive genetic diseases, enabling you to make informed decisions about your reproductive health and the well-being of your future family.
HERES is a clinically validated genetic test designed to detect carriers of medically relevant recessive genetic diseases. Its results enable healthcare professionals to guide couples in making informed and personalized reproductive decisions.
In cases of shared genetic risk, options such as Preimplantation Genetic Diagnosis (PGD), gamete donation, or specialized genetic counseling may be considered. All decisions must be accompanied and supervised by an expert medical team.
HERES Initia analyzes a targeted gene panel, including X-linked diseases.
Its objective is to identify eligible and ineligible donors.
It is designed to screen both oocyte and sperm donors.
Once a donor is assigned to a treatment, a more exhaustive and comprehensive test must be performed, but without the need to collect a new sample.
HERES Seq analyzes more than 300 genes.
It is indicated for patients with reproductive challenges undergoing IVF treatments with autologous or donor gametes.
It allows the detection of mutations responsible for the most prevalent diseases, regardless of ethnicity or geographic area.
It reports variants classified as “pathogenic” or “likely pathogenic”. It also includes all diseases recommended by the SEF (Spanish Fertility Society), as well as those found to be most prevalent after more than 70,000 tests.
Results include a Matching report for the couple or donor-recipient.
HERES Liber analyzes more than 1,200 genes.
It is indicated for clinics, banks, and patients.
It allows testing for result compatibility between samples analyzed with any carrier test, not just HERES.
It offers a clear, understandable, high-quality diagnostic and compatibility assessment, without incurring higher costs.
It allows identifying if both partners are carriers of recessive diseases, even without a family history.
It facilitates informed family planning decisions, offering alternatives such as Preimplantation Genetic Diagnosis (PGD), gamete donation, or specialized counseling.
It can be performed using a saliva or blood sample, with no need for fasting or special preparation.
It is intended for any individual or couple wishing to know their genetic risk before having children.
The HERES test can be performed using a blood sample (two EDTA tubes via venipuncture) or saliva (using a specific kit).
After collection, the sample is sent to the laboratory, where it is analyzed according to the selected test type. Results are delivered within 21 working days, along with a detailed report.
Blood samples must be shipped at room temperature within 72 hours; if this time is exceeded, they must be refrigerated.
Saliva samples can be shipped at room temperature between 72 and 96 hours after collection. It is recommended to avoid extreme temperatures during transport.
Integrating HERES into preventive reproductive medicine allows for the identification of couples at genetic risk prior to conception.
Its use is particularly recommended for individuals wishing to start a family, gamete donors or recipients, couples with a family history of genetic diseases, or those seeking to reduce the risk of transmitting hereditary conditions to their offspring.
